Conclusion
Celbenin has proved its worth in other cases in the Meath Hospital as well, but enough has been exemplified to show its major preeminence in cases where other drugs would fail. Most important of all, Celbenin may be regarded as unlikely to produce resistant strains of staphylococcus aureus and therefore will continue as a permanent weapon against a foe that demands respect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Knudsen, E. T. and Rolinson, G. N. (1960).Brit. Med. J., ii, 700.
Rolinson, Stevens,et al. (1960).Lancet, ii, 564.
Brown, D. M. and Acred, P. (1960). Ibid.,, 568.
Branch, Rodgeret al. (1960).Canad., M. A. J., 83, 991.
Editorial, (1961).Brit. Med. J., i, 886.
Douthwaite, A. H. (1961).Practitioner, 186, 511.
Lowbury, Lillyet al. (1961).Lancet, i, 1318.
Douthwaite, Traffordet al. (1961).Brit. Med. J., ii, 6.
Harding, J. W. and Thompson, R. E. M. (1961).Postgrad. Med. J., 1961,37, 485.
Clinical Staff Conference (1961).Antibiotics and Chemotherapy, ii, No. 9, 537–554.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Montgomery, D. Clinical trial of BRL 1241 (Celbenin). Ir J Med Sci 37, 221–223 (1962). https://doi.org/10.1007/BF02956976
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02956976